Assembly Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASMB research report →
Range $50 – $53
Price Chart
About the company
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV.
- CEO
- Jason A. Okazaki
- IPO
- 2010
- Employees
- 73
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on ASMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $454.39M
- P/E
- 27.06
- PEG
- 0.02
- P/S
- 6.78
- P/B
- 1.62
- EV/EBITDA
- -38.87
- Div Yield
- 0.00%
- Gross Margin
- 99.88%
- Op Margin
- -31.83%
- Net Margin
- -16.57%
- ROE
- -4.40%
- ROIC
- -7.09%
Latest fiscal year · YoY change
- Revenue
- $72.30M+153.5%
- Gross Profit
- $72.17M+363.3%
- Op Income
- $-12,118,000
- Net Income
- $-6,122,000+84.8%
- EPS
- $-0.55+91.8%
- OCF Growth
- +19.6%
- FCF Growth
- +19.5%
- 52W High
- $39.65
- 52W Low
- $19.20
- 50D MA
- $22.32
- 200D MA
- $26.76
- Beta
- 1.22
- RSI (14)
- 53
- Avg Volume
- 307.20K
No earnings-call transcripts are available for ASMB yet.
- Free Float
- 62.9%
- Shares Outstanding
- 20.48M
- Float Shares
- 12.88M
of shares held by institutions
97 13F filers
Buy/sell ratio 0.63. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ASMB, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gilead Sciences, Inc. | 4.98M | 0 |
| Farallon Capital Management, L.L.C. | 1.60M | ▲ 377.00K |
| Paradigm Biocapital Advisors LP | 1.55M | ▲ 888.50K |
| Blackrock, Inc. | 1.49M | ▲ 721.20K |
| Commodore Capital LP | 1.42M | ▲ 415.00K |
| Ra Capital Management, L.P. | 1.02M | 0 |
| Jupiter Topco LLC | 849.31K | ▲ 849.31K |
| Janus Henderson Group Ltd. | 849.31K | ▲ 11.38K |
| Parkman Healthcare Partners LLC | 721.18K | ▲ 309.95K |
| Vanguard Capital Management LLC | 602.93K | ▲ 43.99K |
| Vanguard Group Inc | 572.90K | ▲ 70.79K |
| State Street Corp | 559.59K | ▲ 387.66K |
Held by 107 ETFs
Biggest fund positions in ASMB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Bjorkquist Jeanette M | other | 3,840 |
| Nov 2, 26 | Bjorkquist Jeanette M | sell | 718 |
| Nov 2, 26 | Bjorkquist Jeanette M | sell | 9 |
| Oct 30, 26 | White Nicole S | other | 13,705 |
| Nov 2, 26 | White Nicole S | sell | 2,564 |
| Nov 2, 26 | White Nicole S | sell | 29 |
| Oct 30, 26 | Delaney William E IV | other | 13,705 |
| Oct 30, 26 | Gaggar Anuj | other | 13,705 |
| Nov 2, 26 | Gaggar Anuj | sell | 2,564 |
| Nov 2, 26 | Gaggar Anuj | sell | 29 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASMB coverage
Recent articles, reports, and earnings notes.
No research on ASMB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASMB report →Assembly Biosciences, Inc. (ASMB) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
globenewswire.com · Nov 12
Assembly Biosciences to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 2
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
globenewswire.com · Oct 29
Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)
defenseworld.net · Oct 6
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
globenewswire.com · Oct 5
Best Momentum Stocks to Buy for September 17th
zacks.com · Sep 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.